Characteristics of adults with and without cystic fibrosis-related diabetes

Diabetic Medicine

Volumn 24, Issue 10, 2007, Pages 1143-1148

  Adler, A I ^a,b,c   Gunn, E ^b   Haworth, C S ^b   Bilton, D ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cystic fibrosis related diabetes; Epidemiology; Post transplant diabetes; Prevalence; Secondary diabetes

Indexed keywords

CORTICOSTEROID; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; MAGNESIUM; PANCREAS ENZYME;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; BODY MASS; CONTROL GROUP; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; FORCED EXPIRATORY VOLUME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG FUNCTION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL GLUCOSE TOLERANCE TEST; ORGAN TRANSPLANTATION; PANCREAS INSUFFICIENCY; RISK FACTOR; SCREENING; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE FACTORS; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; MIDDLE AGED; SEX FACTORS;

EID: 34548745167     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02252.x     Document Type: Article

References (31)

1. Bellis G, Cazes MH, Parant A, Gaimard M, Travers C, LeRoux E et al. Cystic fibrosis mortality trends in France. J Cyst Fibrosis 2007 6 : 179 186.
2. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005 146 : 681 687.
3. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: 5-year prospective study. Br Med J 1995 311 : 655 659.
4. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005 28 : 2141 2144.
5. Tofe S, Moreno JC, Maiz L, Alonso M, Escobar H, Barrio R. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. Eur J Endocrinol 2005 152 : 241 247.
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006 29 : S43 48.
7. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
8. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999 30 : 1151 1158.
9. Westaby D. Cystic fibrosis: liver disease. In : Bush, A, Alton, E, Davies, J, Griesenbach, U, Jaffee, A, eds. Cystic Fibrosis in the 21st Century. Basel : Karger 2006 : 251 261.
10. Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005 28 : 1757 1762.
11. Andre P, Balkau B, Born C, Charles MA, Eschwege E. Three-year increase of gamma-glutamyltransferase level and development of Type 2 diabetes in middle-aged men and women: the DESIR cohort. Diabetologia 2006 49 : 2599 25603.
12. Lee DH, Jacobs DR Jr., Gross M, Steffes M. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003 49 : 1358 1366.
13. Ortega E, Koska J, Salbe AD, Tataranni PA, Bunt JC. Serum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children. J Clin Endocrinol Metab 2006 91 : 1419 1422.
14. Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 2005 37 : 246 251.
15. Hardin DS, LeBlanc A, Para L, Seilheimer DK. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes 1999 48 : 1082 1087.
16. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005 28 : 2913 2918.
17. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high-risk population for diabetes. Metabolism 2002 51 : 743 749.
18. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006 113 : 1753 1759.
19. Gomes MB, Piccirillo LJ, Nogueira VG, Matos HJ. Acute-phase proteins among patients with type 1 diabetes. Diabetes Metab 2003 29 : 405 411.
20. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005 22 : 1354 1358.
21. Flora KD, Benner KG. Liver disease in cystic fibrosis. Clin Liver Dis 1998 2 : 51 61.
22. Hadjiliadis D, Madill J, Chaparro C, Tsang A, Wadell TK, Singer LG et al. Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation. Clin Transplant 2005 19 : 773 778.
23. Navas de Solis MS, Merino Torres JF, Mascarell Martinez I, Pinon Selles F. Lung transplantation and the development of diabetes mellitus in adult patients with cystic fibrosis. Arch Bronconeumol 2007 43 : 86 91.
24. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant 2004 23 : S194 201.
25. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006 4 : CD005161.
26. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997 40 : 1439 1448.
27. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995 126 : 515 523.
28. Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. J Pediatr 1991 118 : 715 723.
29. Ma B, Lawson AB, Liese AD, Bell RA, Mayer-Davis EJ. Dairy, magnesium, and calcium intake in relation to insulin sensitivity: approaches to modeling a dose-dependent association. Am J Epidemiol 2006 164 : 449 458.
30. Lopez-Ridaura R, Willett WC, Rimm EB, Liu S, Stampfer MJ, Manson JE et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004 27 : 134 140.
31. Onady G, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. The Cochrane Library 2006 2 : CD004730.